Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Clinical Pharmacokinetics and Pharmacodynamics of Etelcalcetide, a Novel Calcimimetic for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis.

Wu B, Melhem M, Subramanian R, Chen P, Jaramilla Sloey B, Fouqueray B, Hock MB, Skiles GL, Chow AT, Lee E.

J Clin Pharmacol. 2018 Jun;58(6):717-726. doi: 10.1002/jcph.1090. Epub 2018 Mar 13. Review.

PMID:
29534286
2.

Clinical immunogenicity of the d-amino acid peptide therapeutic etelcalcetide: Method development challenges and anti-drug antibody clinical impact assessments.

Kroenke MA, Weeraratne DK, Deng H, Sloey B, Subramanian R, Wu B, Serenko M, Hock MB.

J Immunol Methods. 2017 Jun;445:37-44. doi: 10.1016/j.jim.2017.03.005. Epub 2017 Mar 6.

PMID:
28274835
3.

A Proposal to Redefine Clinical Immunogenicity Assessment.

Mytych DT, Hock MB, Kroenke M, Jawa V, Kaliyaperumal A, Zhou Y.

AAPS J. 2017 May;19(3):599-602. doi: 10.1208/s12248-017-0059-7. Epub 2017 Feb 28.

PMID:
28247192
4.

Pharmacokinetics, Biotransformation, and Excretion of [14C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis.

Subramanian R, Zhu X, Hock MB, Sloey BJ, Wu B, Wilson SF, Egbuna O, Slatter JG, Xiao J, Skiles GL.

Clin Pharmacokinet. 2017 Feb;56(2):179-192. doi: 10.1007/s40262-016-0433-0.

5.

Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality.

Hock MB, Thudium KE, Carrasco-Triguero M, Schwabe NF.

AAPS J. 2015 Jan;17(1):35-43. doi: 10.1208/s12248-014-9684-6. Epub 2014 Nov 8.

6.

Placental transfer of a fully human IgG2 monoclonal antibody in the cynomolgus monkey, rat, and rabbit: a comparative assessment from during organogenesis to late gestation.

Moffat GJ, Retter MW, Kwon G, Loomis M, Hock MB, Hall C, Bussiere J, Lewis EM, Chellman GJ.

Birth Defects Res B Dev Reprod Toxicol. 2014 Apr;101(2):178-88. doi: 10.1002/bdrb.21105.

PMID:
24753333
7.

Immunogenicity/hypersensitivity of biologics.

Leach MW, Rottman JB, Hock MB, Finco D, Rojko JL, Beyer JC.

Toxicol Pathol. 2014 Jan;42(1):293-300. doi: 10.1177/0192623313510987. Epub 2013 Nov 14.

PMID:
24240973
8.

T-cell-dependent antibody responses in the rat: forms and sources of keyhole limpet hemocyanin matter.

Lebrec H, Hock MB, Sundsmo JS, Mytych DT, Chow H, Carlock LL, Joubert MK, Reindel J, Zhou L, Bussiere JL.

J Immunotoxicol. 2014 Jul-Sep;11(3):213-21. doi: 10.3109/1547691X.2013.822948. Epub 2013 Aug 20.

PMID:
23961896
9.

Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates.

Hoofring SA, Lopez R, Hock MB, Kaliyaperumal A, Patel SK, Swanson SJ, Chirmule N, Starcevic M.

Bioanalysis. 2013 May;5(9):1041-55. doi: 10.4155/bio.13.10.

PMID:
23641695
10.

Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity.

Kidani Y, Elsaesser H, Hock MB, Vergnes L, Williams KJ, Argus JP, Marbois BN, Komisopoulou E, Wilson EB, Osborne TF, Graeber TG, Reue K, Brooks DG, Bensinger SJ.

Nat Immunol. 2013 May;14(5):489-99. doi: 10.1038/ni.2570. Epub 2013 Apr 7.

11.

Biomarkers for non-human primate type-I hypersensitivity: antigen-specific immunoglobulin E assays.

Clark D, Shiota F, Forte C, Narayanan P, Mytych DT, Hock MB.

J Immunol Methods. 2013 Jun 28;392(1-2):29-37. doi: 10.1016/j.jim.2013.03.007. Epub 2013 Mar 27.

PMID:
23541488
12.

Disruption of skeletal muscle mitochondrial network genes and miRNAs in amyotrophic lateral sclerosis.

Russell AP, Wada S, Vergani L, Hock MB, Lamon S, Léger B, Ushida T, Cartoni R, Wadley GD, Hespel P, Kralli A, Soraru G, Angelini C, Akimoto T.

Neurobiol Dis. 2013 Jan;49:107-17. doi: 10.1016/j.nbd.2012.08.015. Epub 2012 Sep 4.

PMID:
22975021
13.

Striated muscle activator of Rho signalling (STARS) is a PGC-1α/oestrogen-related receptor-α target gene and is upregulated in human skeletal muscle after endurance exercise.

Wallace MA, Hock MB, Hazen BC, Kralli A, Snow RJ, Russell AP.

J Physiol. 2011 Apr 15;589(Pt 8):2027-39. doi: 10.1113/jphysiol.2011.205468. Epub 2011 Feb 21.

14.

EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.

Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, Zhu S, Kofman AA, Bensinger SJ, Yong WH, Vinters HV, Horvath S, Watson AD, Kuhn JG, Robins HI, Mehta MP, Wen PY, DeAngelis LM, Prados MD, Mellinghoff IK, Cloughesy TF, Mischel PS.

Sci Signal. 2009 Dec 15;2(101):ra82. doi: 10.1126/scisignal.2000446.

15.

Transcriptional control of mitochondrial biogenesis and function.

Hock MB, Kralli A.

Annu Rev Physiol. 2009;71:177-203. doi: 10.1146/annurev.physiol.010908.163119. Review.

PMID:
19575678
16.

SCFCdc4 acts antagonistically to the PGC-1alpha transcriptional coactivator by targeting it for ubiquitin-mediated proteolysis.

Olson BL, Hock MB, Ekholm-Reed S, Wohlschlegel JA, Dev KK, Kralli A, Reed SI.

Genes Dev. 2008 Jan 15;22(2):252-64. doi: 10.1101/gad.1624208.

17.
18.

Orphan nuclear receptor estrogen-related receptor alpha is essential for adaptive thermogenesis.

Villena JA, Hock MB, Chang WY, Barcas JE, Giguère V, Kralli A.

Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1418-23. Epub 2007 Jan 17.

19.

Mitofusins 1/2 and ERRalpha expression are increased in human skeletal muscle after physical exercise.

Cartoni R, Léger B, Hock MB, Praz M, Crettenand A, Pich S, Ziltener JL, Luthi F, Dériaz O, Zorzano A, Gobelet C, Kralli A, Russell AP.

J Physiol. 2005 Aug 15;567(Pt 1):349-58. Epub 2005 Jun 16.

20.

The estrogen-related receptor alpha (ERRalpha) functions in PPARgamma coactivator 1alpha (PGC-1alpha)-induced mitochondrial biogenesis.

Schreiber SN, Emter R, Hock MB, Knutti D, Cardenas J, Podvinec M, Oakeley EJ, Kralli A.

Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6472-7. Epub 2004 Apr 15.

22.

An intron transcriptional enhancer element regulates IL-4 gene locus accessibility in mast cells.

Hural JA, Kwan M, Henkel G, Hock MB, Brown MA.

J Immunol. 2000 Sep 15;165(6):3239-49.

23.

Mutations in RNA polymerase II and elongation factor SII severely reduce mRNA levels in Saccharomyces cerevisiae.

Lennon JC 3rd, Wind M, Saunders L, Hock MB, Reines D.

Mol Cell Biol. 1998 Oct;18(10):5771-9.

Supplemental Content

Support Center